OBSV News and Press, ObsEva SA From 02/18/20

Geneva, Switzerland and Boston, MA – February 18, 2020  – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health today announced that CEO Ernest Loumaye will presen...

Geneva, Switzerland and Boston, MA – February 18, 2019 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health today announced that CEO Ernest Loumaye will present an ...

ObsEva (NASDAQ: OBSV ) initiated with Buy rating and $19 (395% upside) price target at Kempen & Co. Shares up  8%  premarket. More news on: ObsEva SA, Selecta Biosciences, Inc., BioPharmX Corporation, Healthcare stocks news, Stocks on the move, , Read more ...

ObsEva SA (NASDAQ: OBSV ) will provide corporate plans for 2020 and beyond during 2020 JP Morgan Conference in San Francisco. More news on: ObsEva SA, Healthcare stocks news, Read more ...

  Phase 3 linzagolix trials expected to generate additional data in uterine fibroids in Q2:20 with first linzagolix regulatory filing planned for late 2020 Enrollment of linzagolix US and EU Phase 3 trials in endometriosis on track Phase 2 results of OBE022 expected in 2H:20 Corp...

Adaptimmune Therapeutics PLC (NASDAQ: ADAP ) +56%  as SPEAR T-cell platform delivers initial responses in four solid tumors. More news on: Adaptimmune Therapeutics plc, Verona Pharma plc, Mereo BioPharma Group plc, Stocks on the move, Read more ...

ObsEva (NASDAQ: OBSV ) and Yuyuan BioScience Technology have entered into a sublicense agreement to develop and commercialize nolasiban for improving clinical pregnancy and live birth rates in women undergoing embryo transfer following in-vitro fertilization in the People's Republic of Chi...

  Geneva, Switzerland, 13 January 2020 – ObsEva and Yuyuan BioScience Technology (“Yuyuan”) today announced that they have entered into a sublicense agreement to develop and commercialize nolasiban for improving clinical pregnancy and live birth rates in women ...

Geneva, Switzerland and Boston, MA – January 7, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will be participating i...

Gainers: Intra-Cellular Therapies (NASDAQ: ITCI )  +204% . More news on: Intra-Cellular Therapies, Inc., Cassava Sciences, Inc., Microbot Medical Inc., Stocks on the move, Read more ...